Advertisement
Advertisement
U.S. Markets open in 1 hr 23 mins
Advertisement
Advertisement
Advertisement
Advertisement

Brickell Biotech, Inc. (BBI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.4200-0.0400 (-1.16%)
At close: 04:00PM EDT
3.1800 -0.24 (-7.02%)
Pre-Market: 07:16AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4600
Open3.5700
Bid3.1700 x 1400
Ask3.8800 x 1200
Day's Range3.3400 - 3.5800
52 Week Range2.8800 - 37.3500
Volume159,423
Avg. Volume273,000
Market Cap393.464M
Beta (5Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-0.6240
Earnings DateMar 07, 2022 - Mar 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.75
  • GlobeNewswire

    Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developin

  • GlobeNewswire

    Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

    BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell’s management will host a conference call and webcast at 4:30 p.m.

  • GlobeNewswire

    Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

    BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement f

Advertisement
Advertisement